Aparna Parikh, Program Director for the GI Medical Oncology Program at Mass General Brigham, shared a post by Noelia Tarazona, Research Fellow at Mass General Brigham Cancer Center, adding:
“While this question may be less novel than when we first set out to study it, we felt it was important to look at our own data not only in terms of ICI response, but also to better define median overall survival in patients with and without liver metastases. Putting real numbers behind this difference helps frame the true clinical benefit.
These findings underscore the need for modern clinical trials to more thoughtfully distinguish between patients with active liver metastases, no liver disease, and previously treated liver metastases. In that context, we’re excited to be activating a trial in our group at MGBCI that definitively treats liver disease alongside BOT/BAL, with a complementary NRG trial anticipated to launch later this year.”
Quoting Noelia Tarazona‘s post:
“Happy to share our latest work from Mass General Brigham, led by Aparna Parikh.
In MSS metastatic colorectal cancer, liver metastases really matter: patients without liver involvement had markedly better outcomes with ICIs, both in PFS and OS.
Important implications for patient selection and trial design.”
Title: Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Authors: Nussara Pakvisal, Leontios Pappas, Bennett A. Caughey, Nora K. Horick, Noelia Tarazona, Kruti B. Vora, Ben Ouyang, Aditya Pandey, Bryan L. Peacker, Joie Sun, Leyre Zubiri, Kerry L. Reynolds, David P. Ryan, Motaz Qadan, Ryan B. Corcoran, Bruce Giantonio, Jill N. Allen, Elizabeth P. Walsh, Jefferey W. Clark, David T. Ting, Aparna R. Parikh
Read the Full Article.
